» Articles » PMID: 27862214

The Role of Acuity of Illness at Presentation in Early Mortality in Black Children with Acute Myeloid Leukemia

Overview
Journal Am J Hematol
Specialty Hematology
Date 2016 Nov 19
PMID 27862214
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Black patients with acute myeloid leukemia (AML) experience higher mortality than White patients. We compared induction mortality, acuity of illness prior to chemotherapy, and insurance type between Black and White patients to assess whether acuity of presentation mediates the disparity. Within a retrospective cohort of 1,122 children with AML treated with two courses of standard induction chemotherapy between 2004 and 2014 in the Pediatric Health Information System (PHIS) database, the association between race (Black versus White) and inpatient mortality during induction was examined. Intensive Care Unit (ICU)-level resource utilization during the first 72 hours following admission for initial AML chemotherapy was evaluated as a potential mediator. The total effect of race on mortality during Induction I revealed a strong association (unadjusted HR 2.75, CI: 1.18, 6.41). Black patients had a significantly higher unadjusted risk of requiring ICU-level resources within the first 72 hours after initial presentation (17% versus 11%; RR 1.52, CI: 1.04, 2.24). Mediation analyses revealed the indirect effect of race through acuity accounted for 61% of the relative excess mortality during Induction I. Publicly insured patients experienced greater induction mortality than privately insured patients regardless of race. Black patients with AML have significantly greater risk of induction mortality and are at increased risk for requiring ICU-level resources soon after presentation. Higher acuity amongst Black patients accounts for a substantial portion of the relative excess mortality during Induction I. Targeting factors affecting acuity of illness at presentation may lessen racial disparities in AML induction mortality.

Citing Articles

Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma: A Children's Oncology Group Report.

Umaretiya P, Naranjo A, Zhang F, Park J, Weiss B, Granger M JAMA Netw Open. 2025; 8(2):e2458531.

PMID: 39951269 PMC: 11829236. DOI: 10.1001/jamanetworkopen.2024.58531.


Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment.

Umaretiya P, Aziz-Bose R, Kelly C, Bona K Hematology Am Soc Hematol Educ Program. 2024; 2024(1):20-26.

PMID: 39644021 PMC: 11665649. DOI: 10.1182/hematology.2024000527.


A multi-state analysis on the effect of deprivation and race on PICU admission and mortality in children receiving Medicaid in United States (2007-2014).

Mitchell H, Radack J, Passarella M, Lorch S, Yehya N BMC Pediatr. 2024; 24(1):565.

PMID: 39237952 PMC: 11375822. DOI: 10.1186/s12887-024-05031-3.


Healthcare utilization disparities among children with high-risk neuroblastoma treated on Children's Oncology Group clinical trials.

Shoag J, Li Y, Getz K, Huang Y, Hall M, Naranjo A Pediatr Blood Cancer. 2024; 71(10):e31192.

PMID: 38997807 PMC: 11343658. DOI: 10.1002/pbc.31192.


Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia.

Lamba J, Marrero R, Wu H, Cao X, Parcha P, Karol S JAMA Netw Open. 2024; 7(5):e2411726.

PMID: 38753328 PMC: 11099689. DOI: 10.1001/jamanetworkopen.2024.11726.


References
1.
Aplenc R, Alonzo T, Gerbing R, Smith F, Meshinchi S, Ross J . Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood. 2006; 108(1):74-80. PMC: 1895824. DOI: 10.1182/blood-2005-10-4004. View

2.
Simony S, Lund L, Erdmann F, Andersen K, Winther J, Schuz J . Effect of socioeconomic position on survival after childhood cancer in Denmark. Acta Oncol. 2016; 55(6):742-50. DOI: 10.3109/0284186X.2016.1144933. View

3.
Advani A, Atkeson B, Brown C, Peterson B, Fish L, Johnson J . Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study. Cancer. 2003; 97(6):1499-506. DOI: 10.1002/cncr.11213. View

4.
Cooper T, Franklin J, Gerbing R, Alonzo T, Hurwitz C, Raimondi S . AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer. 2011; 118(3):761-9. DOI: 10.1002/cncr.26190. View

5.
Samuels R, Ward V, Melvin P, Macht-Greenberg M, Wenren L, Yi J . Missed Appointments: Factors Contributing to High No-Show Rates in an Urban Pediatrics Primary Care Clinic. Clin Pediatr (Phila). 2015; 54(10):976-82. DOI: 10.1177/0009922815570613. View